Pirfenidone in heart failure with preserved ejection fraction—rationale and design of the PIROUETTE trial
<p><strong>Background</strong></p> <p>The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy and safety of the anti-fibrotic pirfenidone in patients with chronic heart failur...
Main Authors: | Lewis, G, Schelbert, E, Naish, J, Bedson, E, Dodd, S, Eccleson, H, Clayton, D, Jimenez, B, McDonagh, T, Williams, S, Cooper, A, Cunnington, C, Ahmed, F, Viswesvaraiah, R, Russell, S, Neubauer, S, Williamson, P, Miller, C |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2019
|
Similar Items
-
Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone
by: Gavin A. Lewis, et al.
Published: (2022-07-01) -
Pirouette.
by: T. T. Cloete
Published: (2017-03-01) -
Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
by: Francesca Graziani, et al.
Published: (2021-04-01) -
Pirouette : spinner of power.
by: Patrick, Brian, author
Published: (1997) -
György Faludy. <i>Silver Pirouettes.</i> Trans. Paul Sohar.
by: Péter Hargitai
Published: (2016-01-01)